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Carotid Intima-Media Thickness Progression in HIV-Infected Adults
Occurs Preferentially at the Carotid Bifurcation and Is Predicted by
Inflammation
Priscilla Y. Hsue, MD; Rebecca Scherzer, PhD; Peter W. Hunt, MD; Amanda Schnell, BA; Ann F. Bolger, MD; S.C. Kalapus, RDMS;
Kristinalisa Maka, BS; Jeffrey N. Martin, MD, MPH; Peter Ganz, MD; Steven G. Deeks, MD
Background—-Shear stress gradients and inflammation have been causally associated with atherosclerosis development in carotid
bifurcation regions. The mechanism underlying higher levels of carotid intima-media thickness observed among HIV-infected
individuals remains unknown.
Methods and Results—-We measured carotid intima-media thickness progression and development of plaque in the common
carotid, bifurcation region, and internal carotid artery in 300 HIV-infected persons and 47 controls. The median duration of
follow-up was 2.4 years. When all segments were included, the rate of intima-media thickness progression was greater in HIV-
infected subjects compared with controls after adjustment for traditional risk factors (0.055 vs. 0.024 mm/year, P=0.016). Rate
of progression was also greater in the bifurcation region (0.067 vs. 0.025 mm/year, P=0.042) whereas differences were smaller in
the common and internal regions. HIV-infected individuals had a greater incidence of plaque compared with controls in the internal
(23% vs. 6.4%, P=0.0037) and bifurcation regions (34% vs. 17%, P=0.014). Among HIV-infected individuals, the rate of progression
in the bifurcation region was more rapid compared with the common carotid, internal, or mean intima-media thickness; in contrast,
progression rates among controls were similar at all sites. Baseline hsCRP was elevated in HIV-infected persons and was a predictor
of progression in the bifurcation region.
Conclusions—-Atherosclerosis progresses preferentially in the carotid bifurcation region in HIV-infected individuals. hsCRP, amarker
of inflammation, is elevated in HIV and is associated with progression in the bifurcation region. These data are consistent with
a model in which the interplay between hemodynamic shear stresses and HIV-associated inflammation contribute to accelerated
atherosclerosis. ( J Am Heart Assoc. 2012;1:jah3-e000422 doi: 10.1161/JAHA.111.000422.)
Clinical Trial Registration—-URL: http://clinicaltrials.gov. Unique identifier: NCT01519141
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H ighly active antiretroviral therapy has allowed HIV-infected individuals to live longer and face a new set
of health challenges. In particular, HIV-infected individuals
have a higher prevalence of coronary artery disease, which has
been demonstrated both using clinical end points1–3 and utiliz-
ing high-resolution ultrasound to assess carotid artery intima-
media thickness (IMT).4,5 Although some studies have shown
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an increased carotid IMT in the setting of HIV infection,4–6
other studies have not confirmed this finding.7,8 These differ-
ences among studies may be due in part to limited sample size
in some studies, different patient populations, and the method
of imaging utilized by the investigators. The common carotid
bifurcates into the internal and external carotid arteries; the
bifurcation region is also referred to as the carotid bulb. Al-
though most studies have focused on the more readily studied
common carotid artery, fewer studies have also included as-
sessment of the internal carotid and bifurcation regions.
Atherosclerotic lesions tend to occur at areas experiencing
low endothelial shear stress which are local wall stresses that
are generated by patterns of blood flow, such as the carotid bi-
furcation region.9 Low shear stress promotes atherosclerosis
by a variety of mechanisms, including impairment of endothe-
lial function by downregulation of eNOS and upregulation of
endothelin-1,10 increased endothelial uptake of LDL,11 pro-
motion of oxidative stress,12,13 and increased plaque throm-
bogenicity. Low endothelial shear stress also enhances the
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pro-atherogenic effect of chronic inflammation, because it
allows for the attachment and infiltration of inflammatory
cells via activation of NF-κB14,15 and subsequent upregula-
tion of adhesionmolecules, chemokines, and pro-inflammatory
cytokines.16 Low endothelial shear stress has also been im-
plicated in the transition of stable atherosclerotic lesions to
vulnerable plaques resulting in acute coronary syndromes via
a combination of vascular inflammation, change in the extra-
cellular matrix, and wall remodeling.17
On the basis of emerging studies that untreated and treated
HIV disease is associated with chronic inflammation18–20 and
the observations that inflammation preferentially affects cer-
tain regions of the carotid,9 we hypothesized that HIV-infected
individuals may exhibit more rapid IMT progression in the
carotid bifurcation site compared with uninfected individuals.
We therefore assessed carotid IMT in the common, internal,
and bifurcation sites over time in a large cohort of HIV-infected
and -uninfected adults. We also assessed carotid plaque and
development of plaque during follow-up. We also hypothesized
that chronic HIV-associated inflammation would be associated
with accelerated atherosclerosis.
Materials and Methods
Participants
Study participants were obtained from the SCOPE cohort,
which consists of patients followed at San Francisco Gen-
eral Hospital and the San Francisco Veteran’s Affairs Medical
Center. HIV infection status was confirmed using HIV anti-
body testing. Study participants were consecutive volunteers
from the SCOPE study who agreed to participate in the study.
Given our ongoing interest in defining the HIV-associated fac-
tors associated with cardiovascular risk independent of treat-
ment toxicity and high-level viremia,21 we enriched our study
population with rare individuals who controlled HIV replica-
tion indefinitely in absence of therapy (“elite” controllers).22
We categorized the cohort into four groups on the basis of
their treatment status and virologic control at the baseline
visit: (1) antiretroviral treated with undetectable viral loads
using conventional assays (typically <40 to 50 copies/mL),
(2) antiretroviral treated with detectable viremia, (3) antiretro-
viral untreated with detectable viremia (noncontrollers) and
(4) antiretroviral untreated with undetectable viremia (elite
controllers). Uninfected control subjects were recruited from
San Francisco General Hospital, friends/acquaintances of HIV-
infected study participants, and from advertisements placed
around the hospital and San Francisco community. Controls
were documented to be HIV-antibody negative before each
IMT study. All participants were not preselected with respect
to cardiovascular risk factors or coronary artery disease. The
UCSF Committee on Human Research approved this study,
and all individuals provided written informed consent before
study enrollment.
Clinical and Socio-Demographic Characteristics
Detailed interview and assessment of all study participants
was performed by research staff at the time of enrollment. This
assessment included ascertainment of cardiovascular disease
(CVD) risk factors, past and present medication usage, and
drug use. HIV disease characteristics including duration of HIV
infection and current and prior antiretroviral medication were
assessed in HIV-infected individuals.
Laboratory Assays
Blood was drawn in the fasting state and used to measure
total cholesterol, HDL cholesterol, and triglycerides. LDL-
cholesterol was calculated by Friedewald’s formula23 except
for individuals who had triglycerides ≥4.56 mmol/L, where it
was measured directly. C-reactive protein was measured us-
ing a high-sensitivity assay (Dade Behring, Deerfield, IL). The
nadir CD4+ T cell count was defined as the lowest laboratory-
confirmed value before the baseline IMT scan.
Carotid Artery Intima-Media Thickness
We assessed the carotid IMT using the GE Vivid 7 system
and a 10-MHz linear array probe as described previously.5 IMT
was measured in 12 segments that included the near and far
walls of the common carotid, bifurcation region, and internal
carotid region on both the left and right sides, according to
the standardized protocol of the Atherosclerosis Risk in Com-
munities (ARIC) Study.24,25 The right and left carotid arteries
were studied with the head in the midline position and tilted
upward. The probe was then adjusted to obtain the near and
far walls in a parallel orientation and then positioned to obtain
the maximal luminal diameter in the longitudinal plane. Images
were recorded digitally using a cine-loop format for subse-
quent analysis using manual caliper assessment of the digital
images. Within each segment (common, internal, bifurcation
region), IMT was calculated as the average of the near and
far walls of the left and right carotid arteries. A single experi-
enced technician who was blinded to the subjects’ HIV status
performed all the IMT studies and caliper measurements of
the digital images. Both external and internal landmarks were
then identified and used at the subsequent visit to ensure that
the measurements were performed at the same locations on
the follow-up visits. Repeat scans andmeasurements were per-
formed on 12 patients within 1week and repeatmeasurements
were performed on 15 patients; the mean absolute difference
was 0.040 mm with a coefficient of variation of 3.4% and an
intraclass correlation coefficient (ICC) of 0.98.
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Table 1. Comparison of Missing IMT Segments at Each Site in HIV-Infected and HIV-Uninfected Participants
Number of Segments Baseline Last Visit
HIV+ Control P-value HIV+ Control P-value
Internal (4 total) 0 missing 233 (79%) 42 (89%) 0.34 261 (87%) 44 (94%) 0.17
1 missing 38 (13%) 3 (6.4%) 18 (6.0%) 0
2 missing 19 (6.4%) 1 (2.1%) 19 (6.3%) 2 (4.3%)
3 missing 5 (1.7%) 1 (2.1%) 2 (0.7%) 1 (2.1%)
Total 295* 47 300 47
Common (4 total) 0 missing 298 (99%) 47 (100%) 0.99 300 (100%) 47 (100%) na
1 missing 2 (0.7%) 0 0 0
2 missing 0 0 0 0
3 missing 0 0 0 0
Total 300 47 300 47
Bulb (4 total) 0 missing 273 (91%) 46 (98%) 0.26 288 (96%) 45 (96%) 0.30
1 missing 19 (6.3%) 0 11 (3.7%) 1 (2.1%)
2 missing 6 (2.0%) 1 (2.1%) 1 (0.3%) 1 (2.1%)
3 missing 2 (0.7%) 0 0 0
Total 300 47 300 47
Mean (12 total) 0 missing 221 (74%) 42 (89%) 0.061 254 (85%) 43 (91%) 0.20
1 missing 38 (13%) 3 (6.4%) 22 (7.3%) 0
2 missing 25 (8.3%) 0 15 (5.0%) 3 (6.4%)
≥3 missing 16 (5.3%) 2 (4.3%) 9 (3.0%) 1 (2.1%)
Total 300 47 300 47
∗ Five HIV+ participants had no internal IMT segments at baseline. IMT, intima-media thickness: na, not applicable.
For all study participants, the median overall follow-up
time (between baseline and the last available IMT measure-
ment) was 2.4 years (interquartile range, IQR, 1.4–4.1, range:
0.6 to 7.2 years). Follow- time was variable as study enroll-
ment is ongoing, and thus newly enrolled individuals have
shorter follow-up. The median number of IMT procedures was
3 (IQR, 2–8); IMT studies were performed annually on both
HIV-infected individuals and controls. The number of missing
IMT segments at each site was lowest for common and high-
est for internal, and was slightly higher but not statistically
different for HIV-infected compared with control participants
(Table 1). Carotid plaque was defined as a focal region of
IMT greater than 1.5 mm as recommended per the Society
for Vascular Medicine (American Society of Echocardiography)
guidelines.26
Statistical Analysis
The following baseline characteristics were considered as can-
didates for inclusion in multivariable models: demographics,
traditional CVD risk factors, HIV-related factors, comorbidities,
and laboratory parameters. A limited number of characteristics
were collected at follow-up visits, and were included as time-
varying covariates in sensitivity analyses: HIV RNA, antiretro-
viral use, HIV disease category, and hsCRP. CVD risk factors
included smoking (ever vs. never, duration, and current), di-
abetes, systolic and diastolic blood pressure, HDL and total
cholesterol. HIV-related factors included HIV duration, HIV dis-
ease category, viral load, current and nadir CD4 count, prior
opportunistic infection, and antiretroviral use. Comorbidities
included hepatitis C, hypertension, antihypertensive medica-
tion, lipid lowering medication, testosterone medication, prior
coronary artery disease/stroke, current aspirin usage, fam-
ily history of CVD, and BMI. Laboratory parameters included
hsCRP, triglycerides, and glucose. Right-skewed variables such
as hsCRP and CD4 count were log-transformed to normalize
their distributions. Smoothing splines were constructed using
generalized additive models in order to examine the relation-
ship of hsCRP with IMT.
The association ofHIV statuswith carotid IMT levels and pro-
gression was assessed using linearmixedmodels, with random
intercepts and slopes using a first-order antedependence co-
variance structure. Interaction terms between HIV status and
time were used to determine whether the rate of progression
DOI: 10.1161/JAHA.111.000422 Journal of the American Heart Association 3
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in IMT differed between HIV-infected and -uninfected partici-
pants. The association of HIV status with prevalence of plaque
at baseline was assessed using Poisson regression with a ro-
bust variance estimator, and the association of HIV status with
risk of incident plaque was assessed using Cox proportional
hazards models. We applied a staged modeling approach, first
adjusting for demographic characteristics, next adjusting for
traditional CVD risk factors (as listed above), and finally ad-
justing for hsCRP. “Interaction terms between each covariate
(including HIV status) and time were used to determine and
compare rates of change in IMT.”
Adjusted IMT progression was calculated for HIV-infected
and -uninfected participants using population marginal means
from a linear mixed model with dependent variable of IMT, con-
taining all terms in the finalmodel. To account for thosewithout
measured IMT at a given study visit due to loss to follow-up or
drop-out, we performed sensitivity analyses using an inverse
probability weighting approach by modeling each participant’s
probability of having measured IMT at each time point. Re-
sults were similar to the primary observed models (data not
shown). All analyses were conducted using SAS version 9.2
(SAS Institute, Inc., Cary, NC).
Results
Baseline Characteristics
Carotid IMT was measured in 300 HIV-infected and 47 HIV-
uninfected participants. On average, HIV-infected participants
were older (median age 47 vs. 43), were more often African
American, had a higher prevalence of smoking, hypertension,
and dyslipidemia, and had higher levels of hsCRP (Table 2).
The median duration of HIV infection was 13 years, and 70% of
participants had used antiretroviral therapy for a median du-
ration of 5 years. Baseline characteristics stratified by disease
category are provided in Table 3.
Association of HIV infection with Baseline
Carotid IMT Levels
At baseline, mean levels of IMT were significantly higher in
HIV-infected participants compared with controls at all sites
(Figure 1A). After demographic adjustment (Table 4), HIV infec-
tion remained associated with higher overall IMT levels com-
pared with control participants at all measured sites: internal
(+0.176 mm, P=0.0037), common (+0.095 mm, P<0.0001),
bifurcation (+0.257 mm, P=0.0003), and mean IMT
(+0.158 mm, P=0.0002). This HIV association was unatten-
uated after adjusting for traditional CVD risk factors. Further
adjustment for baseline hsCRP and change from baseline in
hsCRP resulted in little change in the association of HIV infec-
tion with higher IMT (data not shown).
Rates of Change in IMT by HIV Infection Status
After adjusting for demographic, CVD risk factors, and hsCRP,
HIV infection was associated with faster progression for mean
IMT (+0.031 mm/year, P=0.016, Figure 1B and Table 5). This
difference in IMT progression rateswasmost clearly seen in the
bifurcation region (+0.040 mm/year, P=0.042). In contrast,
the difference between HIV-infected and control participants
in progression did not reach statistical significance for inter-
nal (+0.033 mm/year, P=0.16) and common IMT (+0.012
mm/year, P=0.20). Similar results were seen in more parsi-
monious models that retained only statistically significant fac-
tors (Table 6). Additional sensitivity analyses showed similar
results when we excluded those with hyperlipidemia, diabetes,
or hypertension.
Among HIV-infected individuals, the rate of progression
in the bifurcation region was more rapid compared with
the common carotid (+0.034 mm/year, 95% CI, 0.025–
0.043, P<0.0001), internal (+0.014, 95% CI, 0.002–0.026,
P=0.018), or mean IMT (+0.012, 95% CI, 0.003–0.021,
P=0.0057). By contrast, rates of progression among the unin-
fected controls were similar at all sites, and tests of differences
did not reach statistical significance (P>0.38 for all). As a sen-
sitivity analysis, 5% of individuals with the largest outliers were
removed, and the difference in rate of progression between
HIV-infected and -uninfected individuals remained similar to
the original analysis (as shown in Table 7).
Rates of Change in IMT by HIV Treatment Status
and Disease Category
We also compared rates of IMT progression of HIV-infected
participants by disease category. All four disease categories
showed higher baseline IMT levels compared to controls
(P<0.0001 vs. controls at all sites). All four disease categories
appeared to have faster rates of overall IMT progression rel-
ative to controls, but after controlling for other risk factors,
the differences reached statistical significance only for elite
controllers (P<0.01 vs. controls for internal and mean) and
treated unsuppressed patients (P<0.05 vs. controls for bifur-
cation and mean). The rates of progression within each region
(common, internal, bifurcation) exhibited comparable trends to
that observed for overall mean IMT. After adjustment for demo-
graphics, CVD risk factors, and hsCRP, rates of IMT progression
were numerically higher in HIV-infected groups compared with
the controls, although most differences were not statistically
different. Similar results were seen in models that included
disease category as a time-varying covariate.
hsCRP and IMT Progression
At baseline, hsCRP values were higher among all HIV-infected
subjects (median 17.14 nmol/L, IQR, 7.62–41.91) compared
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Table 2. Baseline Characteristics of HIV-Infected and HIV−Uninfected Participants
ParameterHeadings HIV-Infected (n=300) HIV−uninfected (n=47) P-value
Age (y) 47 (41–53) 43 (38–51) 0.048†
Gender
Male 268 (89%) 38 (81%) 0.16
Female 29 (10%) 9 (19%)
Transgender M->F 3 (1%) 0
Race
Caucasian 181 (60%) 36 (77%) 0.011†
African American 75 (25%) 3 (6%)
Latino 30 (10%) 4 (9%)
Other 14 (5%) 4 (9%)
History of CAD/CVA 23 (8%) 1 (2%) 0.22
Cigarette smoking (ever) 207 (69%) 24 (51%) 0.020†
Diabetes mellitus 21 (7%) 1 (2%) 0.33
Hypertension 84 (28%) 4 (9%) 0.0035†
Hyperlipidemia treatment 51 (17%) 1 (2%) 0.0040†
LDL (mmol/L) 2.62 (2.08–3.23) 2.80 (2.21–3.90) 0.058
HDL (mmol/L) 1.05 (0.85–1.26) 1.26 (1.08–1.56) <.0001†
TG (mmol/L) 1.64 (1.07–2.84) 0.99 (0.72–1.58) <.0001†
T Chol (mmol/L) 4.69 (3.95–5.49) 4.77 (4.15–5.72) 0.34
hsCRP (nmol/L) 17.14 (7.62–41.91) 10.48 (3.81–29.52) 0.027†
BMI (kg/m2) 25 (23–28) 25 (23–30) 0.96
Hepatitis C virus antibody seropositivity 68 (23%) 0 (0%) <0.0001†
Duration of HIV infection (y) 13 (8–17)
ARV use (ever) 228 (76%)
HAART use (ever) 209 (70%)
HAART duration (y)* 5.0 (3.4–6.3)
NRTI use (ever) 228 (76%)
NRTI duration (y)* 6.9 (4.2–10.1)
NRTI use (ever) 143 (48%)
NNRTI duration (y)* 2.4 (1.0–4.0)
PI use (ever) 195 (65%)
PI duration (y)* 4.6 (3.0–6.1)
Current CD4+ T cells/μL 434 (272–653)
Nadir CD4+ T cells/μL 172 (50–329)
Plasma HIV RNA (copies/mL)
<75 159 (53%)
75–1999 56 (19%)
2000–9999 35 (12%)
>10 000 50 (17%)
Data are presented as median (IQR) or numbers (percent).
HAART, highly active antiretroviral therapy; IQR, interquartile range; CAD/CVA, cardiovascular/cerebrovascular disease; ARV, antiretroviral; NRTI, nucleoside reverse transcriptase
inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TG, triglycerides; y, years.
*Duration of antiretroviral use among ever users.
†p<0.05.
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Table 3. Baseline Characteristics of HIV-Infected and HIV−Uninfected Participants by Disease Category
Parameter Elite Controller (n=26) Treated Unsuppressed (n=71) Treated Suppressed (n=135) Untreated Unsuppressed (n=68) HIV− (n=47)
Age (y) 50 (42–52) 45 (41–55) 49 (43–53) 44 (39–50) 43 (38–51)
Gender
Male 20 (77%) 63 (89%) 127 (94%) 58 (85%) 38 (81%)
Female 6 (23%) 8 (11%) 7 (5%) 8 (12%) 9 (19%)
Transgender M->F 0 0 1 (1%) 2 (3%) 0
Race
Caucasian 15 (58%) 39 (55%) 93 (69%) 34 (50%) 36 (77%)
African American 7 (27%) 20 (28%) 19 (14%) 29 (43%) 3 (6%)
Latino 3 (12%) 9 (13%) 14 (10%) 4 (6%) 4 (9%)
Other 1 (4%) 3 (4%) 9 (7%) 1 (1%) 4 (9%)
History of CAD/CVA 0 2 (3%) 14 (10%) 7 (10%) 1 (2%)
Cigarette smoking (ever) 21 (81%) 53 (75%) 84 (62%) 49 (72%) 24 (51%)
Diabetes mellitus 1 (4%) 7 (10%) 10 (7%) 3 (4%) 1 (2%)
Hypertension 8 (31%) 21 (30%) 38 (28%) 17 (25%) 4 (9%)
Hyperlipidemia treatment 4 (16%) 10 (14%) 36 (27%) 1 (1%) 1 (2%)
LDL (mmol/L) 2.46 (1.77–3.26) 2.64 (1.90–3.15) 2.69 (2.23–3.36) 2.51 (2.08–3.03) 2.80 (2.21–3.64)
HDL (mmol/L) 1.15 (0.90–1.31) 0.97 (0.77–1.18) 1.08 (0.85–1.31) 1.05 (0.90–1.23) 1.26 (1.08–1.56)
TG (mmol/L) 1.35 (0.97–1.91) 1.74 (1.10–2.80) 2.31 (1.42–4.24) 1.11 (0.78–1.45) 0.99 (0.73–1.59)
T Chol (mmol/L) 4.15 (3.51–5.56) 4.49 (3.67–5.36) 5.00 (4.46–5.90) 4.26 (3.62–4.85) 4.77 (4.15–5.72)
hsCRP (nmol/L) 14.29 (8.57–22.86) 13.33 (5.71–35.24) 19.05 (6.67–41.91) 20.00 (07.62–45.72) 10.48 (3.81–29.52)
BMI (kg/m2) 28 (26–33) 25 (23–28) 25 (22–28) 25 (23–29) 25 (23–30)
Hepatitis C virus 13 (50%) 18 (26%) 28 (21%) 16 (24%) 1 (2%)
antibody seropositivity
Data are presented as median (IQR) or numbers (percent).
IQR, interquartile range; CAD/CVA, cardiovascular/cerebrovascular disease; TG, triglycerides.
with uninfected controls (median 10.48 nmol/L, IQR, 3.81–
29.52, P=0.027). A graphical examination showed that in-
creasing hsCRP appeared to be associated with both higher
levels of IMT and faster progression in the bifurcation region
(Figure 2). In a fully adjusted model (Table 5), there was a
trend toward an independent association between hsCRP and
bifurcation progression; this effect was stronger in the parsi-
monious model which demonstrated that hsCRP was indepen-
dently associated with statistically significant progression in
the bifurcation region (Table 6). The HIV effects were nearly
the same in the full model as compared with the parsimonious
model.
Evaluation of plaque at baseline and followup
The prevalence of plaque at baseline in any segment was
greater in HIV-infected individuals compared with uninfected
participants (50% vs. 23%, P<0.0001); even after multivari-
able adjustment for traditional CVD risk factors and hsCRP,
HIV infection remained associated with 2-fold higher risk of
plaque (95% CI, 1.26–3.14, P=0.0033). HIV-infected subjects
also had a higher prevalence of plaque compared with con-
trols in the internal (23% vs. 6.4%, P=0.0037) and bifurcation
(34% vs. 17%, P=0.014) segments, whereas the prevalence in
the common segment was low in both groups (5.3% vs. 0%,
P=0.14).
After excluding individuals with plaque present at baseline,
HIV-infected individuals had a higher risk of incident plaque
over the follow-up period (44% vs. 2.8%, P<0.0001). Similarly,
the incidence of plaque was significantly higher in the internal
(27% vs. 4.5% P=0.0007) and bifurcation segments 29% vs.
5.1%, P=0.0010) of HIV-infected persons compared with con-
trols whereas little difference was seen in the common carotid
region (8.1% vs. 2.1%, P=0.22).
Discussion
CVD continues to be an important health concern among HIV-
infected individuals.27,28 Although a number of studies have
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Figure 1. IMT Levels and Progression by Region and HIV status. (A) Unadjusted IMT levels at baseline: The IMT levels at baseline for all
HIV-infected individuals were significantly higher as compared with uninfected controls at the internal, common, bifurcation region, and mean
IMT (P<0.001 for all). (B) Mean IMT progression (adjusted): After adjustment for demographics, traditional factors, and hsCRP, IMT progression
in the carotid bifurcation region and calculated mean IMT were higher among HIV-infected individuals as compared with controls, while there was
no statistically significant difference in IMT progression in the internal and common carotid progression.
demonstrated that individuals with HIV infection are at in-
creased risk for myocardial infarction,2,29,30 the underlying
mechanisms associated with CVD and HIV infection remain
to be described. Assessment of IMT using high-resolution ul-
trasound is a noninvasive technique that is predictive of future
cardiovascular events and represents a direct quantification of
subclinical vascular disease.26 Using this well-accepted mea-
surement of atherosclerotic disease, we performed a com-
prehensive longitudinal assessment of IMT in a large hetero-
geneous cohort of HIV-infected and uninfected individuals,
and found that HIV infection was independently associated
with more rapid IMT progression in the carotid bifurcation re-
gion, with weaker associations in the other segments. Chronic
inflammation—as defined by hsCRP levels at baseline—was
Figure 2. Unadjusted association of hsCRP with IMT levels and IMT progression in the bifurcation region: In the bifurcation region, higher
hsCRP levels were associated with higher levels of IMT at baseline (A) and IMT progression over time (B) in both HIV-infected and HIV-uninfected
participants. Higher solid line denotes predicted IMT (with dotted 95%CI confidence bounds) calculated from unadjusted generalized additive
model (GAM). P-values are from spline and linear portion of the fit. A) HIV (red): Spline: p=0.090; linear: p=0.0008; Control (blue): Spline:
p=0.0081; linear: p<.0001. B) HIV (red): Spline: p=0.29; linear: p=0.017 Control (blue): Spline: p=0.016; linear: p=0.21.
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Table 4. Association of HIV-Infection with Overall Levels of Internal, Common, Bifurcation, and Mean IMT
IMT Measure HIV-Infected (N=300†) HIV− (N=47†)
Internal IMT (mm)
Mean difference of HIV-infected vs. controls (95% CI)
Adjusted for demographics‡ 0.176 (0.058, 0.295)
Adjusted for demographics and traditional CVD risk factors¶ 0.175 (0.049, 0.302)
Common IMT (mm)
Mean difference of HIV-infected vs. controls (95% CI)
Adjusted for demographics‡ 0.095 (0.049, 0.141)
Adjusted for demographics and traditional CVD risk factors¶ 0.108 (0.059, 0.158)
Bifurcation IMT (mm)
Mean difference of HIV-infected vs. controls (95% CI)
Adjusted for demographics‡ 0.257 (0.117, 0.396)
Adjusted for demographics and traditional CVD risk factors¶ 0.251 (0.102, 0.400)
Mean IMT (mm)
Mean difference of HIV-infected vs. controls (95% CI)
Adjusted for demographics‡ 0.158 (0.075, 0.241)
Adjusted for demographics and traditional CVD risk factors¶ 0.158 (0.069, 0.247)
Estimates are calculated from linear mixed models with random intercepts and slopes.
†N denotes number of participants included in analysis.
‡Adjusted for age, sex, race, and time.
¶Adjusted for age, sex, race, time, smoking status, diabetes, systolic blood pressure, diastolic blood pressure, total cholesterol, and HDL cholesterol.
elevated in HIV-infected subjects and was independently as-
sociated with IMT progression in the bifurcation region using
a parsimonious model, although this effect was diminished
in the fully adjusted model. HIV infection was independently
associated with prevalence of plaque at baseline and was
associated with greater incidence of plaque during follow-
up; additionally, HIV-infected individuals had higher rates of
plaque in the bifurcation and internal carotid regions as com-
pared to controls. When considered in the context of emerg-
ing data from the general population, which suggest that the
carotid bifurcation region is uniquely prone to the effects of
chronic inflammation, our data are consistent with a model
in which chronic HIV-associated inflammation causes accel-
erated atherosclerosis in the bifurcation region, and that this
process collectively contributes to excess cardiovascular risk
associated with HIV infection.
Carotid IMT studies in the HIV-infected population have
yielded conflicting results. Initial reports showed that HIV-
infected individuals on antiretroviral therapy and uninfected
controls with similar metabolic disturbances had similar lev-
els of IMT, as assessed by the right common carotid artery.31
In the ACTG 5078 study, no difference in IMT was detected
among HIV-infected individuals and well-matched controls ei-
ther at baseline7 or over time.32 All of these studies focused
on assessment of the common carotid artery exclusively. In
contrast, prior studies from our group (which included all seg-
ments) showed that HIV-infected individuals had higher IMT at
baseline and at 1-year follow-up compared to controls.5 Both
HIV infection and antiretroviral therapy were found to be as-
sociated with higher IMT in another large study;4 interestingly,
the differences between HIV-infected and -uninfected groups
were greatest in the carotid bifurcation region. Investigators
from the FRAM study found that there was a stronger asso-
ciation of HIV infection with carotid IMT in the internal and
bifurcation region than the common carotid.6 In the Women’s
Interagency HIV Study, when only the common carotid artery
was assessed, no difference in mean IMT was found between
HIV-infected and uninfected controls; however, frequency of
carotid lesions, which included measurements of the inter-
nal and bifurcation region, was significantly increased among
individuals with more advanced HIV disease.8 Our study ex-
tends these latter cross-sectional observations by showing dif-
ferential progression of IMT over time. Individuals with HIV
infection may be exposed to the effects of HIV for a much
smaller proportion of their lifetime compared to chronic tra-
ditional risk factors such as cigarette smoking. As a result, in
cross-sectional studies, the effects of HIV may be less promi-
nent than other traditional risk factors, because the outcome
measure is the absolute amount of IMT. This is in contrast
to studies of IMT progression, which begin when the individ-
uals is already infected with HIV and may allow more insight
into the direct effects of HIV infection. Recently, in the SUN
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Table 5. Multivariable Analysis of Factors Associated with Carotid Intima-Medial Thickness Progression in HIV-Infected and HIV−
Uninfected Participants (Full Model)
Factor
Internal IMT (mm/year)
Estimate (95% CI)
Common IMT (mm/year)
Estimate (95% CI)
Bifurcation IMT (mm/year)
Estimate (95% CI)
Mean IMT (mm/year)
Estimate (95% CI)
Progression in HIV 0.053 (0.038, 0.067),
P<0.0001†
0.033 (0.028, 0.039),
P<0.0001†
0.067 (0.055, 0.078),
P<0.0001†
0.055 (0.047, 0.063),
P<0.0001†
Progression in HIV-controls 0.020 (−0.024, 0.063),
P=0.37
0.022 (0.005, 0.039),
P=0.012†
0.025 (−0.012, 0.062),
P=0.19
0.024 (−0.000, 0.048),
P=0.050
HIV vs. HIV-control 0.033 (−0.013, 0.079),
P=0.16
0.012 (−0.006, 0.031),
P=0.20
0.040 (0.002, 0.078),
P=0.042†
0.031 (0.006, 0.056),
P=0.016†(difference in rate of progression)*
Other factors in model:
Age (per decade) 0.032 (0.016, 0.049),
P=0.0002†
0.004 (−0.002, 0.011),
P=0.21
0.012 (−0.001, 0.026),
P=0.075
0.019 (0.010, 0.028),
P<0.0001†
Female vs. male 0.025 (−0.025, 0.074),
P=0.33
0.009 (−0.010, 0.029),
P=0.35
0.004 (−0.038, 0.046),
P=0.84
0.010 (−0.017, 0.036),
P=0.47
African American vs. Caucasian 0.013 (−0.025, 0.051),
P=0.50
0.008 (−0.008, 0.023),
P=0.32
0.025 (−0.006, 0.056),
P=0.11
0.014 (−0.006, 0.034),
P=0.17
Latino/other vs. Caucasian 0.009 (−0.031, 0.049),
P=0.66
0.007 (−0.009, 0.023),
P=0.37
0.010 (−0.023, 0.042),
P=0.56
0.007 (−0.014, 0.028),
P=0.52
Diabetic −0.033 (−0.091,
0.026), P=0.27
−0.011 (−0.033,
0.012), P=0.35
−0.068 (−0.113,
−0.024), P=0.0030†
−0.039 (−0.069,
−0.009), P=0.012†
Ever smoker 0.032 (0.003, 0.062),
P=0.031
−0.001 (−0.013,
0.010), P=0.80
0.018 (−0.005, 0.041),
P=0.13
0.016 (0.000, 0.031),
P=0.044†
SBP (per 10 mm Hg) −0.006 (−0.021,
0.009), P=0.45
0.002 (−0.004, 0.008),
P=0.54
0.001 (−0.011, 0.013),
P=0.83
−0.000 (−0.008,
0.008), P=0.97
DBP (per 10 mm Hg) 0.002 (−0.017, 0.022),
P=0.83
0.003 (−0.005, 0.011),
P=0.47
0.003 (−0.012, 0.019),
P=0.68
0.003 (−0.008, 0.013),
P=0.59
HDL (per 0.26 mmol/L) −0.004 (−0.014,
0.007), P=0.50
0.000 (−0.004, 0.004),
P=0.93
−0.002 (−0.011,
0.006), P=0.56
−0.001 (−0.007,
0.004), P=0.65
T Chol (per 0.26 mmol/L) 0.002 (−0.001, 0.005),
P=0.13
0.001 (−0.001, 0.002),
P=0.38
0.000 (−0.002, 0.003),
P=0.85
0.001 (−0.001, 0.003),
P=0.23
hsCRP (per doubling) 0.001 (−0.007, 0.008),
P=0.87
−0.001 (−0.004,
0.002), P=0.61
0.005 (−0.001, 0.011),
P=0.073
0.002 (−0.002, 0.006),
P=0.30
Results reported as estimated IMT progression in mm/year (95% confidence interval).
Estimates are calculated from linear mixed models with random intercepts and slopes.
*HIV vs. HIV− uninfected control difference in progression is shown adjusted for traditional CVD risk factors and hsCRP.
†p < 0.05.
SBP, systolic blood pressure; DBP diastolic blood pressure.
study, HIV-infected individuals with suppressed viral loads had
decreased IMT progression assessed in the common carotid
artery.33
The clinical implications of our observations remain to be de-
fined. Early pathology studies have established that atheroscle-
rotic lesions occur at vascular branch points.34,35 More specif-
ically, among individuals without HIV infection, atherosclerotic
lesions appear to occur at the carotid artery bifurcation.9,36,37
Vascular branch points are associated with low endothelial
shear stress, which likely enhances atherogenesis through
multiple mechanisms.9–13,37–41 Importantly, low endothelial
shear stress may increase vascular susceptibility to the ef-
fects of chronic inflammation, perhaps by causing upregula-
tion of adhesionmolecules, chemokines, and pro-inflammatory
cytokines.16 Our observation that changes in IMT are localized
to areas known to be susceptible to the atherogenic effect
of inflammation is broadly consistent with the observations
that markers of inflammation are elevated in HIV disease and
associated with cardiovascular events.18,42 Among individu-
als without HIV infection in the Framingham Offspring Study,
IMT of the internal carotid but not the common carotid signifi-
cantly improved cardiovascular risk prediction, and authors of
this study suggest that IMT of the internal carotid should be
measured in addition to common carotid artery.43 Similar to
our study, a single sonographer was used to perform all of the
scans. Future studies will be needed to determine whether or
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Table 6. Multivariable Analysis of Factors Associated with Carotid Intima-Media Thickness Progression in HIV-Infected and HIV−
Uninfected Participants (Parsimonious Models)
Factor
Internal IMT (mm/year)
Estimate (95% CI)
Common IMT (mm/year)
Estimate (95% CI)
Bifurcation IMT (mm/year)
Estimate (95% CI)
Mean IMT (mm/year)
Estimate (95% CI)
Progression in HIV 0.052 (0.039, 0.066),
P<0.0001†
0.034 (0.029, 0.039),
P<0.0001†
0.066 (0.055, 0.077),
P<0.0001†
0.055 (0.048, 0.063),
P<0.0001†
Progression in HIV-controls 0.017 (−0.022, 0.056),
P=0.39
0.022 (0.006, 0.038),
P=0.0072†
0.023 (−0.012, 0.057),
P=0.19
0.021 (−0.001, 0.044),
P=0.063
HIV vs. HIV-control 0.035 (−0.007, 0.077),
P=0.099
0.011 (−0.006, 0.028),
P=0.21
0.045 (0.010, 0.080),
P=0.012†
0.035 (0.012, 0.058),
P=0.0034†(difference in rate of progression)*
Other factors in model
Age (per decade) 0.030 (0.015, 0.046),
P=0.0002†
0.017 (0.009, 0.026),
P=0.0001†
Diabetic −0.062 (−0.105,
−0.020), P=0.0047†
−0.033 (−0.062,
−0.004), P=0.027†
Ever smoker 0.028 (0.001, 0.055),
P=0.043†
0.017 (0.002, 0.032),
P=0.025
hsCRP (per doubling) 0.007 (0.001, 0.013),
P=0.016†
Results reported as estimated IMT progression in mm/year (95% confidence interval).
Parsimonious models above remove statistically nonsignificant time × factor terms, but retain HIV status, time, demographics, traditional CVD, and hsCRP.
Estimates are calculated from linear mixed models with random intercepts and slopes.
*HIV vs. HIV− control difference in progression is shown adjusted for traditional CVD risk factors and hsCRP.
†p< 0.05.
not internal carotid IMT modifies CV risk in the setting of HIV
infection.
We also explored the association of HIV-associated factors
on IMT progression. To address this question, we have re-
cruited a large number of individuals who have long-term HIV
infection, but lack evidence of high-level viral replication and
are not receiving potentially toxic antiretroviral drugs (elite
controllers). As we previously reported, the elite controllers
in this study had at baseline relatively high levels of overall
IMT (indeed, the degree of IMT was comparable to that in
the prototypic long-term treated HIV-infected subject).21 Our
current study extends these finding and shows that elite con-
trollers have faster rates of progression than HIV-uninfected
controls, suggesting that HIV disease factors independent of
treatment exposure, high-level viremia, and advanced immun-
odeficiency contribute to this process over time. We also found
that optimally treated patients (ie, those with uninterrupted an-
tiretroviral use maintaining an undetectable viral load) had no
attenuation in the rate of progression in the bifurcation region.
This finding suggests that fully effective therapy for HIV infec-
tion does not completely restore the rate of IMT progression
to what is observed among uninfected controls.
Our study has several important limitations. Although this
is a single-center study that allowed us to have great control
over the imaging quality and imaging protocol, we recognize
that accurate measurement of the carotid bifurcation region
as well as internal carotid regions may be challenging for mul-
ticenter studies. An additional study limitation was that most
of our covariates were measured only at baseline, which lim-
ited our ability to assess the effects of changes in risk factors
and disease characteristics on IMT progression. An additional
limitation is that our control group was much smaller than
our HIV-infected group. However, our finding of greater IMT
levels among HIV-infected individuals at baseline compared
to controls is consistent with previous studies including the
larger FRAM study6 and the study by Lorenz et al.4 Although
some imaging protocols exclude plaques from IMT assess-
ments, we measured IMT whether or not plaque was present
which is the same method endorsed by the American Soci-
ety of Echocardiography26, large observational cohorts,44 and
clinical trials using IMT as the end point.45 For the purposes
of our study, the distinction between plaque and IMT was not
critical as we were evaluating IMT as a vascular marker of car-
diovascular risk, and IMT in the presence or absence of plaque
is an independent predictor of increased risk. Although there
were differences in baseline characteristics between our HIV-
infected and control participants, we found that levels of IMT
and rates of progression remained increased in HIV-infected
persons even after multivariable adjustment for demographic
and traditional CVD risk factors. As is true with any observa-
tional study, unmeasured confounders may be present among
our HIV-infected individuals, which distinguish them from unin-
fected controls, although we tried to adjust for all of the known
risk factors.
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Table 7. Effect of Removal of Outliers on Carotid Intima-Media Thickness Progression in HIV-Infected and HIV−Uninfected
Participants
Factor
Internal IMT (mm/year)
Estimate (95% CI)
Common IMT (mm/year)
Estimate (95% CI)
Bifurcation IMT (mm/year)
Estimate (95% CI)
Mean IMT (mm/year)
Estimate (95% CI)
Original results
Progression in HIV 0.053 (0.038, 0.067),
P<0.0001†
0.033 (0.028, 0.039),
P<0.0001†
0.067 (0.055, 0.078),
P<0.0001
0.055 (0.047, 0.063),
P<0.0001†
Progression in HIV-controls 0.020 (−0.024, 0.063),
P=0.37
0.022 (0.005, 0.039),
P=0.012†
0.025 (−0.012, 0.062),
P=0.19
0.024 (−0.000, 0.048),
P=0.050
HIV vs. HIV-control 0.033 (−0.013, 0.079),
P=0.16
0.012 (−0.006, 0.031),
P=0.20
0.040 (0.002, 0.078),
P=0.042
0.031 (0.006, 0.056), PP
= 0.016(difference in rate of progression)*
Results after removing outliers
Progression in HIV 0.048 (0.037, 0.059),
P<0.0001†
0.031 (0.026, 0.036),
P<0.0001†
0.069 (0.059, 0.080),
P<0.0001†
0.053 (0.047, 0.060),
P<0.0001†
Progression in HIV-controls 0.017 (−0.016, 0.050),
P=0.31
0.019 (0.005, 0.033),
P=0.0092
0.029 (−0.002, 0.060),
P=0.068
0.025 (0.004, 0.045),
P=0.018
HIV vs. HIV-control (difference in rate of progression)* 0.031 (−0.005, 0.066),
P=0.090
0.013 (−0.002, 0.028),
P=0.099
0.037 (0.005, 0.070),
P=0.026†
0.028 (0.007, 0.050),
P=0.011†
∗HIV vs. HIV− control difference in progression is shown adjusted for traditional CVD risk factors and hsCRP.
†p<0.05.
To address the question of whether a small group of individuals is driving the overall mean rate of progression, we looked at a number of influence statistics (including Cook’s D, the
PRESS statistic, and the likelihood distance) from the mixed linear regression model, accounting for the within-subject clustering. As a sensitivity analysis, we excluded participants with
large influence statistics. When we removed the 5% of individuals with the largest outliers, the difference in rate of progression between HIV-infected and -uninfected participants
remained similar to the original analysis, as shown above.
Summary/Conclusions
In conclusion, over a median follow-up period of 2.4 years, HIV
infection and inflammation as assessed by hsCRP were both
independently associated with more rapid IMT progression in
the carotid bifurcation region, even after adjustment for tradi-
tional CVD risk factors. In contrast, there was no statistically
significant difference in IMT progression in the internal and
common carotid regions between HIV-infected individuals and
controls. Development of plaque occurred more frequently in
the bifurcation and internal carotid regions in HIV-infected in-
dividuals as compared with controls and was less frequent in
the common carotid in both groups. As data from uninfected
individuals demonstrate that the carotid bifurcation region is
uniquely prone to inflammatory effects as a result of low en-
dothelial shear stress, our findings suggest that the impact of
HIV infection on vascular function may be most apparent in
branch points due to the effects of inflammation. These ob-
servations may have important implications for future studies
regarding the pathogenesis, epidemiology and management of
HIV-associated CVD.
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